Premium
FDA LABA Warning: Is There Anything New Here?
Author(s) -
Weiss S T
Publication year - 2010
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2010.58
Subject(s) - medicine , pharmacology
The FDA advisory on long‐acting β‐agonists (LABAs) is not based on new data but on ongoing safety concerns about this class of medication. Not to be ignored are the potential safety risks of short‐acting β‐agonists (SABAs). Clinical Pharmacology & Therapeutics (2010) 87 6, 638–639. doi: 10.1038/clpt.2010.58